ITI Appoints Regulatory Affairs VP

Louise Peltier has been appointed vice president of regulatory affairs at Immunomic Therapeutics, Inc. (ITI). ITI is a privately-held biotechnology company developing vaccines based on its LAMP technology.
 
Ms. Peltier has more than 30 years of experience in the regulatory space and has worked both as a consultant and in-house at PharmAthene, Northwest Biotherapeutics, Caris Life Sciences, Guilford Pharmaceuticals and Centocor, where she oversaw regulatory filings, meetings and pharmacovigilance, in both the U.S. and abroad.
 
“Louise has experience both in-house and consulting and understands the ever-evolving regulatory environment,” said William Hearl, Ph.D., chief executive officer of ITI. “As ITI continues to develop as a company and we continue to take our products through the regulatory process, we look forward to success under Louise’s guidance.”